A 57-year-old man with MI is admitted in cardiac emergency. Which of the following drug might cause unexpected results based on CYP2C19 genotype of patient?
## **Core Concept**
The question revolves around the concept of pharmacogenomics, specifically the impact of the CYP2C19 genotype on drug metabolism. CYP2C19 is an enzyme that belongs to the cytochrome P450 family and plays a crucial role in metabolizing various drugs. Variations in the CYP2C19 gene can lead to poor, intermediate, extensive, or ultra-rapid metabolism of drugs, affecting their efficacy and toxicity.
## **Why the Correct Answer is Right**
The correct answer, , is likely related to clopidogrel, a prodrug that requires metabolic activation by CYP2C19 to its active form. This active form then inhibits platelet activation and aggregation by irreversibly binding to the P2Y12 receptor on platelets. Individuals with a poor metabolizer genotype for CYP2C19 (e.g., CYP2C19*2/*2) have reduced conversion of clopidogrel to its active metabolite, potentially leading to decreased efficacy of the drug in preventing thrombotic events. This is particularly relevant in patients with myocardial infarction (MI) who are being treated with clopidogrel.
## **Why Each Wrong Option is Incorrect**
- **Option A:** Without specific details on the drugs listed, we can infer based on common knowledge that not all drugs are significantly affected by the CYP2C19 genotype. For instance, drugs that are not metabolized by CYP2C19 or do not have a significant pharmacokinetic interaction with CYP2C19 polymorphisms would not produce unexpected results based on this genotype.
- **Option B:** Similarly, another drug not significantly impacted by CYP2C19 genotype variations would not show unexpected results.
- **Option D:** A fourth option, presumably another drug, would also not be relevant if it does not interact significantly with CYP2C19.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that clopidogrel is a prodrug requiring activation by CYP2C19. Patients who are poor metabolizers of CYP2C19 may have a reduced response to clopidogrel, potentially necessitating alternative antiplatelet therapy. This interaction highlights the importance of pharmacogenomics in tailoring drug therapy to an individual's genetic makeup.
## **Correct Answer: .**